Unknown

Dataset Information

0

The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer.


ABSTRACT: BACKGROUND:Ramucirumab plus docetaxel (RAM+DOC) is expected to prolong survival in patients with advanced non-small cell lung cancer (NSCLC); however, the efficacy and safety for older patients remains unknown. The objective of this study was to evaluate the efficacy and safety of RAM+DOC in patients 75?years and older. METHODS:We retrospectively reviewed consecutive patients with advanced NSCLC who had received RAM+DOC treatment at three institutions. We compared the efficacy and safety in patients 75?years and older to those under 75?years of age. RESULTS:A total of 114 patients were identified. The median progression-free survival, time to treatment failure and overall survival was 3.6 (95% CI: 0.4-6.7), 3.1 (95% CI: 2.4-3.9) and 11.2 months (95% CI: 5.6-16.8) in the older group (N =?23), and 4.2 (95% CI: 3.3-5.0), 3.4 (95% CI: 3.3-5.0) and 12.2 months (95% CI: 9.1-15.4) in the younger group (N =?91), respectively. Survival curves were similar for each group, while the objective response rate was 30.4% (95% CI: 13.2-52.9%) in older patients and 35.2% (95% CI, 25.4-45.9%) for the younger group. A total of 22 older patients (95.7%) and 73 (80.2%) younger patients received primary prophylactic pegylated-granulocyte-colony stimulating factor (PEG-G-CSF). Four older patients (17.3%) and 14 younger patients (15.3%) discontinued RAM+DOC due to adverse events. CONCLUSIONS:RAM+DOC is expected to be efficacious and tolerable in older patients when supported with prophylactic PEG-G-CSF therapy. KEY POINTS:Significant findings of the study ?PFS, OS, and ORR in older patients were similar to those under 75?years of age. ?Safety of RAM+DOC was well tolerated in older patients with prophylactic PEG-G-CSF. ?Prophylactic PEG-G-CSF with RAM+DOC may contribute to better efficacy. What this study adds ?This study suggests that RAM+DOC with prophylactic PEG-G-CSF is expected to be a useful option in older patients with advanced NSCLC.

SUBMITTER: Sakaguchi T 

PROVIDER: S-EPMC7262941 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer.

Sakaguchi Tadashi T   Furuya Naoki N   Ito Kentaro K   Hida Naoya N   Morikawa Kei K   Komase Yuko Y   Inoue Takeo T   Hataji Osamu O   Mineshita Masamichi M  

Thoracic cancer 20200414 6


<h4>Background</h4>Ramucirumab plus docetaxel (RAM+DOC) is expected to prolong survival in patients with advanced non-small cell lung cancer (NSCLC); however, the efficacy and safety for older patients remains unknown. The objective of this study was to evaluate the efficacy and safety of RAM+DOC in patients 75 years and older.<h4>Methods</h4>We retrospectively reviewed consecutive patients with advanced NSCLC who had received RAM+DOC treatment at three institutions. We compared the efficacy and  ...[more]

Similar Datasets

| S-EPMC7290397 | biostudies-literature
| S-EPMC10733157 | biostudies-literature
| S-EPMC8902090 | biostudies-literature
| S-EPMC8350088 | biostudies-literature
| S-EPMC9096414 | biostudies-literature
| S-EPMC6887726 | biostudies-literature
| S-EPMC8758423 | biostudies-literature
| S-EPMC9446552 | biostudies-literature
| S-EPMC10761202 | biostudies-literature
| S-EPMC4870343 | biostudies-literature